

1 **Supplementary Material**

2 **Supplementary Figure 1: Food intake.**

3 (A, B, C) Food intake of Lipistase- or vehicle-treated LDLrKO, LDLrKO-PPAR α KO, and
4 APOEKO mice monitored over a period of 8 months.

5

6 **Supplementary Figure 2: Effect of Lipistase on 3T3-L1 cell differentiation.**

7 **(A)** Quantification of oil red O assay of 3T3L1 differentiated cells (day 5) treated with the PPAR γ
8 ligand Rosiglitazone (Rosi, 1 μ M), the PPAR α ligand WY-14 643 (WY, 1 μ M) and Lipistase (Lip,
9 160 pg/mL). * $p < 0.05$. **(B)** Lipistase effect on mRNA expression levels of genes encoding
10 adipose-secreted proteins (Leptin, Adiponectin, Resistin and Adipsin), a lipogenic transcription
11 factor (SREBP-1c) and lipogenic markers (ACC1, FAS and ADFP) during the differentiation of
12 3T3-L1 cells at the indicated days.

13

14 **Supplementary Figure 3: Effect of Lipistase on the levels of hepatic total cholesterol,
15 cholesterol esters, and triglycerides.**

16 The levels of the abovementioned lipids were measured in LDLrKO and LDLrKO-PPAR α KO
17 after a 10 month-treatment with Lipistase.

18

19 **Supplementary Figure 4: Comparative mRNA expression levels of genes involved in fatty acid
20 uptake, fatty acid catabolism and lipogenesis in muscle, adipose tissue, and liver.**

21 mRNA expression levels of markers for fatty acid uptake, fatty acid catabolism, and lipogenesis
22 measured in LDLrKO and LDLrKO-PPAR α KO after a 10 month treatment with Lipistase.

23

24 **Supplementary Figure 5: Lipistase increases oxygen consumption in APOEKO mice.**

1 Oxygen consumption measured after a 10 month-treatment with Lipistase (*p < 0.05; nAPOEKO =
2 4 per group).

3

4 **Supplementary Figure 6. Athero-protective effects of Lipistase in APOEKO mice.**

5 **(A)** Oil red O staining of aortic roots from mice treated with Lipistase or vehicle (Control) starting
6 at 3 weeks of age for 3 months (left panel). **(B)** Oil red O stained aortic roots dissected from
7 offspring of Lipistase- or vehicle- (Control) treated mice. These offsprings were also treated after
8 weaning for 3 months. The representative images (left panels) show plaque area in aortic roots.

9

10 **Supplementary Figure 7: Lipistase reduced postprandial hypertriglyceridemia.**

11 Progression of plasma triglyceride levels within 5 hours after administration of 300 µL of soy oil by
12 gavage (Time 0) to mice fasted for 12 hours after a 3 month Lipistase or vehicle (Control)
13 treatment.

14

15 **Supplementary Figure 8: Fertility and viability.**

16 **(A & B)** Number of alive or dead pups at 3 months post-weaning after Lipistase or vehicle
17 (Control) treated parent mice before conception, mothers during gestation and lactation, and
18 pups after weaning.

19 **Supplementary Table 1: Kown beneficial effects of Lipistase components on lipid metabolism.**

20

Lipistase components	Proven actions on lipid metabolism
zinc	antioxidant activity ¹ , vascular protection ²
iron	tissue oxygenation ³ , cardiac protection ⁴
selenium enriched yeast	anti-atherosclerosis ^{3, 5}
vitamin B3	oxidative metabolism ⁶
vitamins B9, B6, B12, E and F	anti-atherosclerosis ⁶
magnesium	anti-atherosclerosis ⁷

fish oil	plasma lipid lowering via lipid catabolism promotion ⁸ , anti-atherosclerosis ⁹⁻¹¹
evening primrose oil	anti-inflammatory activity ¹² , vascular protection ¹³
rapeseed oil	plasma lipid lowering ¹⁴ via lipid catabolism promotion in liver ^{15, 16}
olive oil	antioxidant activity ¹⁷
grapeseed oil	activation of mitochondrial oxidation in skeletal muscle ¹⁸
<i>Fucus vesiculosus</i>	anti-obesity ¹⁹⁻²¹ , anti-inflammatory activity ^{22, 23} , plasma lipid lowering via lipid absorption inhibition ²⁴ , antioxidant activity ²⁵⁻²⁷
<i>Chondrus crispus</i> , <i>Palmaria palmata</i> , <i>Crithmum maritimum</i>	antioxidant activity ²⁸⁻³¹
<i>Vitis vinifera</i>	anti-atherosclerosis ³²⁻³⁷ , antioxidant activity ³⁸⁻⁴² , plasma lipid lowering via lipid absorption inhibition ^{43, 44}
<i>Allium sativum</i>	plasma lipid lowering ⁴⁵⁻⁴⁷ , via hepatic lipogenesis inhibition ^{48, 49} , antioxidant activity ⁵⁰ , anti-atherosclerosis ⁵¹⁻⁵³

1

2 1. Bray TM, Bettger WJ. The physiological role of zinc as an antioxidant. *Free Radic Biol*

3 *Med* 1990;**8**:281-291.

4 2. Pearce LL, Wasserloos K, St Croix CM, Gandley R, Levitan ES, Pitt BR. Metallothionein,

5 nitric oxide and zinc homeostasis in vascular endothelial cells. *J Nutr* 2000;**130**:1467S-

6 1470S.

7 3. Reilly C. The Nutritional Trace Metals. Blackwell Publishing Ltd, 2004.

8 4. Lauffer RB. Iron stores and the international variation in mortality from coronary artery

9 disease. *Med Hypotheses* 1991;**35**:96-102.

10 5. Cinemre H, Bilir C, Gokosmanoglu F, Kadakal F. Anti-Saccharomyces cerevisiae

11 antibodies in acute myocardial infarction. *J Investig Med* 2007;**55**:444-449.

- 1 6. McDowell LR. *Vitamins in Animal and Human Nutrition*. Iowa State University Press,
2 2000.
- 3 7. Ashmead. *Intestinal absorption of metal ions*. Thomas Publisher, 1985.
- 4 8. Rustan AC, Christiansen EN, Drevon CA. Serum lipids, hepatic glycerolipid metabolism
5 and peroxisomal fatty acid oxidation in rats fed omega-3 and omega-6 fatty acids. *Biochem*
6 *J* 1992;**283** (Pt 2):333-339.
- 7 9. Connor WE, DeFrancesco CA, Connor SL. N-3 fatty acids from fish oil. Effects on plasma
8 lipoproteins and hypertriglyceridemic patients. *Ann N Y Acad Sci* 1993;**683**:16-34.
- 9 10. Lopez D, Moller M, Denicola A, Casos K, Rubbo H, Ruiz-Sanz JI *et al*. Long-chain n-3
10 polyunsaturated fatty acid from fish oil modulates aortic nitric oxide and tocopherol status
11 in the rat. *Br J Nutr* 2008;**100**:767-775.
- 12 11. Margioris AN. Fatty acids and postprandial inflammation. *Curr Opin Clin Nutr Metab Care*
13 2009;**12**:129-137.
- 14 12. Yoshimoto-Furuie K, Yoshimoto K, Tanaka T, Saima S, Kikuchi Y, Shay J *et al*. Effects of
15 oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids
16 and uremic skin symptoms in hemodialysis patients. *Nephron* 1999;**81**:151-159.
- 17 13. Jack AM, Keegan A, Cotter MA, Cameron NE. Effects of diabetes and evening primrose oil
18 treatment on responses of aorta, corpus cavernosum and mesenteric vasculature in rats. *Life*
19 *Sci* 2002;**71**:1863-1877.
- 20 14. Gulesserian T, Widhalm K. Effect of a rapeseed oil substituting diet on serum lipids and
21 lipoproteins in children and adolescents with familial hypercholesterolemia. *J Am Coll Nutr*
22 2002;**21**:103-108.
- 23 15. Christiansen RZ, Christiansen EN, Bremer J. The stimulation of erucate metabolism in
24 isolated rat hepatocytes by rapeseed oil and hydrogenated marine oil-containing diets.
25 *Biochim Biophys Acta* 1979;**573**:417-429.

- 1 16. Murata M, Ide T, Hara K. Reciprocal responses to dietary diacylglycerol of hepatic enzymes
2 of fatty acid synthesis and oxidation in the rat. *Br J Nutr* 1997;**77**:107-121.
- 3 17. Visioli F, Bellomo G, Montedoro G, Galli C. Low density lipoprotein oxidation is inhibited
4 in vitro by olive oil constituents. *Atherosclerosis* 1995;**117**:25-32.
- 5 18. Chainier F, Roussel D, Georges B, Meister R, Rouanet JL, Duchamp C *et al.* Cold
6 acclimation or grapeseed oil feeding affects phospholipid composition and mitochondrial
7 function in duckling skeletal muscle. *Lipids* 2000;**35**:1099-1106.
- 8 19. Bocanegra A, Bastida S, Benedi J, Rodenas S, Sanchez-Muniz FJ. Characteristics and
9 nutritional and cardiovascular-health properties of seaweeds. *J Med Food* 2009;**12**:236-258.
- 10 20. Maeda H, Tsukui T, Sashima T, Hosokawa M, Miyashita K. Seaweed carotenoid,
11 fucoxanthin, as a multi-functional nutrient. *Asia Pac J Clin Nutr* 2008;**17 Suppl 1**:196-199.
- 12 21. Moro CO, Basile G. Obesity and medicinal plants. *Fitoterapia* 2000;**71 Suppl 1**:S73-82.
- 13 22. Cardoso ML, Xavier CA, Bezerra MB, Paiva AO, Carvalho MF, Benevides NM *et al.*
14 Assessment of Zymosan-Induced Leukocyte Influx in a Rat Model using Sulfated
15 Polysaccharides. *Planta Med* 2009.
- 16 23. Patankar MS, Oehninger S, Barnett T, Williams RL, Clark GF. A revised structure for
17 fucoidan may explain some of its biological activities. *J Biol Chem* 1993;**268**:21770-21776.
- 18 24. Ikeda I, Tanaka K, Sugano M, Vahouny GV, Gallo LL. Inhibition of cholesterol absorption
19 in rats by plant sterols. *J Lipid Res* 1988;**29**:1573-1582.
- 20 25. Lee S, Lee YS, Jung SH, Kang SS, Shin KH. Anti-oxidant activities of fucosterol from the
21 marine algae *Pelvetia siliquosa*. *Arch Pharm Res* 2003;**26**:719-722.
- 22 26. Ruperez P, Ahrazem O, Leal JA. Potential antioxidant capacity of sulfated polysaccharides
23 from the edible marine brown seaweed *Fucus vesiculosus*. *J Agric Food Chem*
24 2002;**50**:840-845.

- 1 27. Zaragoza MC, Lopez D, M PS, Poquet M, Perez J, Puig-Parellada P *et al.* Toxicity and
2 antioxidant activity in vitro and in vivo of two *Fucus vesiculosus* extracts. *J Agric Food*
3 *Chem* 2008;**56**:7773-7780.
- 4 28. Matsuhira B, Urzua CC. Heterogeneity of carrageenans from *Chondrus crispus*.
5 *Phytochemistry* 1992;**31**:531-534.
- 6 29. Meot-Duros L, Magne C. Antioxidant activity and phenol content of *Crithmum maritimum*
7 *L.* leaves. *Plant Physiol Biochem* 2009;**47**:37-41.
- 8 30. Yuan H, Song J, Zhang W, Li X, Li N, Gao X. Antioxidant activity and cytoprotective
9 effect of kappa-carrageenan oligosaccharides and their different derivatives. *Bioorg Med*
10 *Chem Lett* 2006;**16**:1329-1334.
- 11 31. Yuan YV, Carrington MF, Walsh NA. Extracts from dulse (*Palmaria palmata*) are effective
12 antioxidants and inhibitors of cell proliferation in vitro. *Food Chem Toxicol* 2005;**43**:1073-
13 1081.
- 14 32. Andriambelason E, Kleschyov AL, Muller B, Beretz A, Stoclet JC, Andriantsitohaina R.
15 Nitric oxide production and endothelium-dependent vasorelaxation induced by wine
16 polyphenols in rat aorta. *Br J Pharmacol* 1997;**120**:1053-1058.
- 17 33. Diebolt M, Bucher B, Andriantsitohaina R. Wine polyphenols decrease blood pressure,
18 improve NO vasodilatation, and induce gene expression. *Hypertension* 2001;**38**:159-165.
- 19 34. Ekshyyan VP, Hebert VY, Khandelwal A, Dugas TR. Resveratrol inhibits rat aortic vascular
20 smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. *J*
21 *Cardiovasc Pharmacol* 2007;**50**:83-93.
- 22 35. Lee B, Moon SK. Resveratrol inhibits TNF-alpha-induced proliferation and matrix
23 metalloproteinase expression in human vascular smooth muscle cells. *J Nutr*
24 2005;**135**:2767-2773.

- 1 36. Leifert WR, Abeywardena MY. Cardioprotective actions of grape polyphenols. *Nutr Res*
2 2008;**28**:729-737.
- 3 37. Perez-Jimenez J, Saura-Calixto F. Grape products and cardiovascular disease risk factors.
4 *Nutr Res Rev* 2008;**21**:158-173.
- 5 38. Cestaro B, Simonetti P, Cervato G, Brusamolino A, Gatti P, Testolin G. Red wine effects on
6 peroxidation indexes of rat plasma and erythrocytes. *Int J Food Sci Nutr* 1996;**47**:181-189.
- 7 39. Goni I, Brenes A, Centeno C, Viveros A, Saura-Calixto F, Rebole A *et al.* Effect of dietary
8 grape pomace and vitamin E on growth performance, nutrient digestibility, and
9 susceptibility to meat lipid oxidation in chickens. *Poult Sci* 2007;**86**:508-516.
- 10 40. Rodrigo R, Rivera G, Orellana M, Araya J, Bosco C. Rat kidney antioxidant response to
11 long-term exposure to flavonol rich red wine. *Life Sci* 2002;**71**:2881-2895.
- 12 41. Roig R, Cascon E, Arola L, Blade C, Salvado MJ. Moderate red wine consumption protects
13 the rat against oxidation in vivo. *Life Sci* 1999;**64**:1517-1524.
- 14 42. Simonetti P, Ciappellano S, Gardana C, Bramati L, Pietta P. Procyanidins from *Vitis*
15 *vinifera* seeds: in vivo effects on oxidative stress. *J Agric Food Chem* 2002;**50**:6217-6221.
- 16 43. Pal S, Naissides M, Mamo J. Polyphenolics and fat absorption. *Int J Obes Relat Metab*
17 *Disord* 2004;**28**:324-326.
- 18 44. Tebib K, Besancon P, Rouanet JM. Dietary grape seed tannins affect lipoproteins,
19 lipoprotein lipases and tissue lipids in rats fed hypercholesterolemic diets. *J Nutr*
20 1994;**124**:2451-2457.
- 21 45. Kojuri J, Vosoughi AR, Akrami M. Effects of anethum graveolens and garlic on lipid
22 profile in hyperlipidemic patients. *Lipids Health Dis* 2007;**6**:5.
- 23 46. Sobenin IA, Andrianova IV, Demidova ON, Gorchakova T, Orekhov AN. Lipid-lowering
24 effects of time-released garlic powder tablets in double-blinded placebo-controlled
25 randomized study. *J Atheroscler Thromb* 2008;**15**:334-338.

- 1 47. Yeh YY, Lin, R. I., Yeh, S. M. & Evens, S. Garlic reduces plasma cholesterol in
2 hypercholesterolemic men maintaining habitual diets. In: T. OHOTTJWST, ed. Food
3 Factors for Cancer Prevention. Tokyo: Springer, 1997:226-230.
- 4 48. Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds:
5 human and animal studies. *J Nutr* 2001;**131**:989S-993S.
- 6 49. Yeh YY, Yeh SM. Garlic reduces plasma lipids by inhibiting hepatic cholesterol and
7 triacylglycerol synthesis. *Lipids* 1994;**29**:189-193.
- 8 50. Ide N, Lau BH. Garlic compounds minimize intracellular oxidative stress and inhibit
9 nuclear factor-kappa b activation. *J Nutr* 2001;**131**:1020S-1026S.
- 10 51. Campbell JH, Efendy JL, Smith NJ, Campbell GR. Molecular basis by which garlic
11 suppresses atherosclerosis. *J Nutr* 2001;**131**:1006S-1009S.
- 12 52. Lau BH. Suppression of LDL oxidation by garlic. *J Nutr* 2001;**131**:985S-988S.
- 13 53. Slowing K, Ganado P, Sanz M, Ruiz E, Tejerina T. Study of garlic extracts and fractions on
14 cholesterol plasma levels and vascular reactivity in cholesterol-fed rats. *J Nutr*
15 2001;**131**:994S-999S.

16
17
18

1 **Supplementary Table 2: Primers used for real-time RT-qPCR**

Gene	Forward (3'-5')	Reverse (3'-5')
CD36	CAT.NO. QT01058253 (Qiagen quantitect)	
ACOX1	CAT.NO. QT01775851 (Qiagen quantitect)	
BFE	TGTTCTTGGCTTGGGAACG	TCCCCACCCTTGCAAAAAG
UCP3	CAT.NO. QT00115339 (Qiagen quantitect)	
TNF α	CAT.NO. QT00104006 (Qiagen quantitect)	
MCP-1	CAT.NO. QT00167832 (Qiagen quantitect)	
MIP1- α	TTCTCTGTACCATGACACTCTGC	CGTGGAATCTTCCGGCTGTAG
SREBP-1c	CAGCTCAGAGCCGTGGTGA	TTGATAGAAGACCGGTAGCGC
ACC1	ATTGGGCACCCCAGAGCTA	CCCCTCCTTCAACTTGCT
FAS	CCTCTGATCAGTGGCTCCTC	GGATTCGGGAATACAAGTGGC
SCD1	AGATCTCCAGTTCTTACACGACCAC	GACGGATGTCTTCTTCCAGGTG
Elovl3	CAT.NO. QT00115675 (Qiagen quantitect)	
DGAT1	CGTGGGCGACGGCTACT	GAAACCACTGTCTGAGCTGAACA
DGAT2	GCCCCGACGAAAACA	GTCTTGGAGGGCTGAGAGGAT
ADFP	CTACGACGACACCGAT	CATTGCGGAATACGGAG
PPAR γ 2	GCCCACGAACTTCGGAATC	TGCGAGTGGTCTTCCATCAC
CEBP α	GAGCTGAGTGAGGCTCTCATTCT	TGGGAGGCAGACGAAAAAAC
LPL	AGTGGCCGAGAGCGAGAAC	CCACCTCCGTGTAAATCAAGAAG
aP2	CCGCAGACGACAGGAAGG	AGGGCCCCGCCATCT
Leptin	AACCCTCATCAAGACCATTGTCA	CCTCTGCTTGGCGGATACC
Adiponectin	GCACTGGCAAGTTCTACTGCAA	GTAGGTGAAGAGAACGGCCTTGT
Resistin	GCTGCTGCCAAGGCTGAT	TCTCCTTCCACCATGTAGTTTCC
Adipsin	GCCTGATGTCCTGCATCAACT	GCGCAGATTGCAGGTTGTC
Cyclo (housekeeping)	TTTGACTTGCGGGCATT	GGACGCTCTCCTGAGCTACAGA
36B4 (housekeeping)	ACCTCCTTCTTCCAGGCTTT	CCCACCTTGTCTCCAGTCTTT

2




3




4 CD36: cluster of differentiation 36; ACOX1: peroxisomal acyl-coenzyme A oxidase 1; TNF α :

5 tumor necrosis factor alpha; MCP-1: monocyte chemotactic protein-1; MIP1- α : macrophage


6 inflammatory protein 1-alpha; SREBP-1c: sterol regulatory element-binding protein 1-c; FAS: fatty

- 1 acid synthase; SCD1: stearoyl-CoA desaturase 1; Elovl3: elongation of very long chain fatty acids
- 2 3; DGAT1: diglyceride acyltransferase 1; DGAT2: diglyceride acyltransferase 2; ADFP: adipose
- 3 differentiation-related protein; PPAR γ 2: peroxisome-proliferator activated receptor gamma 2;
- 4 CEBP α : CCAAT/enhancer-binding protein alpha; LPL: lipoprotein lipase; aP2: adipocyte protein
- 5 2; Cyclo: cyclophilin B; 36B4: acidic ribosomal phosphoprotein P0.
- 6


A**B****C**




Supplementary Figure 2



Supplementary Figure 3







Supplementary Figure 5

A

Control




Lipistase





B

Control





Lipistase





Supplementary Figure 7

A**B**

Supplementary Figure 8